Purchase this database of 10+ companies developing NKT cell based therapeutics
Invariant natural killer T (iNKT) cells constitute a distinct population of T cells, that serve many functional and regulatory roles for the immune system. The cells express an invariant aβ T-cell receptor (TCR) as well as a number of cell surface molecules in common with natural killer (NK) cells, which differentiates the cells from the more common T-cell populations. Furthermore, iNKT cells recognize glycolipid antigens presented by the non-polymorphic MHC class I-like molecule, CD1d, instead of peptide antigen fragments.
Chimeric antigen receptor (CAR) engineered NKT cells have shown early, but promising results in solid tumors. A clinical study was performed in children with relapsed or resistant neuroblastoma and objective responses were observed after treatment (1).
Figure 1: Depiction of the differences and similarities between canonical CAR T cell mechanisms and CAR-NKT mechanisms. The figure is from Creative Biolabs website.
Stargazing Bio Research have collected all the natural killer T cell companies currently known to work in the industry.
The database/list contains more than 10 NKT therapeutics companies with confirmed adoptive cell assets under development, this being preclinical or clinical development. Natural killer T cell therapeutics companies is an evolving field, and this database may change and expand, bringing in new NKT cell therapy companies as more launch in the future.